Chemotherapy
Pharmacology
Pharmacokinetics of the Combination Pyrimethamine with Sulfadoxine and Mefloquine (FANSIMEF) in Chinese Volunteers and the Relative Bioavailability of a Lacquered TabletWang N.S.a · Guo X.B.b · Liu Q.D.a · Fu L.C.b · Li G.Q.b · Arnold K.cInstitutes of aClinical Pharmacology, and bTropical Diseases, Guangzhou College of Traditional Chinese Medicine, Guangdong, China; cRoche Asian Research Foundation, Hong Kong
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 09, 2009
Issue release date: 1990
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
The oral single-dose pharmacokinetics and bioavailability of mefloquine (M) in combination with pyrimethamine (P) and sulfadoxine (S) from a single non-lacquered tablet (NL; M 250 mg, P 25 mg, S 500 mg) and two lacquered tablets (L; M 125 mg, P 12.5 mg, S 250 mg) were investigated in 6 healthy Chinese volunteers. The plasma concentrations of P and S were measured by high-performance liquid chromatography with UV detector over 11 days and the plasma concentrations of M were measured by gas chromatography with electron capture for 63 days. The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear one-compartment model. The model-independent pharmacokinetic parameters such as elimination half-life and total clearance of P and S in the present study were not appreciably different from those reported previously. The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h kg, and 14.8 1/kg, respectively. Compared to previously published data on M in Thai patients, Caucasian, Brazilian and African subjects, it was found that the elimination half-life in Chinese subjects was similar to that in Thai patients, but different from Caucasian, Brazilian and African subjects. There were significant differences in total clearance and volume of distribution among Chinese subjects and Thai patients. The differences in pharmacokinetic behaviour of M between subject groups needs to be examined further. The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean ± SD) of 0.98 ± 0.06,1.28 ± 0.20 and 1.02 ± 0.17, respectively. The combination of mefloquine (M) with pyrimethamine (P) and sulfadoxine (S; Fansimef) is an effective antimalarial in adults and children [1–3]. P and S inhibit two different enzymes (dihydrofolate reductase and dihydropterate synthetase) in the plasmodial folate biosynthesis pathway and the synergistic action of these drugs is enhanced by the additive effect of M, a quinoline methanol derivative [4]. The triple combination also delays the development of resistance [5] and in vitro studies confirm this efficacy even when there is a P-S resistance [6]. The pharmacokinetics of M in combination with P and S have been described in Brazilian [7], African [8], Caucasian [8, 9], and Thai patients [10] and Thai volunteers [11]. The present study investigates the pharmacokinetics of M in combination with P and S and the bioavailability of these drugs from non-lacquered and lacquered tablets in a cross-over design in 6 Chinese male volunteers.
© 1990 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: September 09, 2009
Issue release date: 1990
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
